Candel Therapeutics, Inc.
Company Stats
- Market Cap
- $798.9M
- as of Sep 30, 2026
- Enterprise Value
- $725.2M
- Shares Outstanding
- 76.5M
- Free Float
- 71.1%
Income Statement
- Operating Income
- -$48.3M
- Net Income
- -$38.2M
- EBITDA
- -$47.4M
- Non-cash Impairment
- $90,000
Cash Flow
- Free Cash Flow
- -$38.9M
- FCF Yield
- -4.9%
- Owner FCF Yield
- -5.3%
Balance Sheet
- Cash & Equivalents
- $119.7M
- Total Debt
- $46.1M
- Net Cash
- $73.6M
Returns & Capital
- SBC, 3Y Avg
- $4.1M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$38.9M | — |
| FY2024 | — | -$27.0M | — |
| FY2023 | — | -$34.7M | — |
| FY2022 | $125,000 | -$32.7M | -26172.8% |
| FY2021 | $125,000 | -$24.1M | -19242.4% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 5, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges